Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Janet Pope, ACR 2022: Nintedanib for systemic sclerosis-associated interstitial lung disease – analysis of the SENSCIS Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 28th 2022

The SENSCIS Trial (NCT02597933) was a phase 3 randomised, double-blind, placebo controlled study, which investigated the efficacy and safety of nintedanib in the treatment of patients with systemic sclerosis associated interstitial lung disease. In this touchIMMUNOLOGY interview, it was a pleasure to talk with Dr. Janet Pope (University of Western Ontario, London, ON, Canada) to discuss her analysis, which assessed outcomes by organ damage using a modified version of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI).

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial.‘ (Abstract number: 1528) was presented at the ACR Convergence, November 10–14, 2022.

Questions

  1. What is the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) and what are its aims? (0:16)
  2. Could you give us a brief overview of the SENSCIS study and its primary findings? (0:49)
  3. What were the aims and design of this analysis? (2:32)
  4. How effective were the SCTC-DI scores as a measure of organ damage? (3:58)
  5. What did the findings teach us about the efficacy of nintedanib? (5:36)

Disclosures: Janet Pope has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup